Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis.
Update on Leukodystrophies: A Historical Perspective and Adapted Definition.
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: No.
Olig2-lineage cells preferentially differentiate into oligodendrocytes but their processes degenerate at the chronic demyelinating stage of proteolipid protein-overexpressing mouse.
Grey matter damage in multiple sclerosis: A pathology perspective.
[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No.]
Paraoxonase 1 in neurological disorders.
Depression as a predictor of occupational transition in a multiple sclerosis cohort.
Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis.
Modeling the Presence of Myelin and Edema in the Brain Based on Multi-Parametric Quantitative MRI.
Management of neurogenic bladder in patients with multiple sclerosis.
[Anesthetic Management of Three Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy].
Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Endothelium.
Astrocyte matricellular proteins that control excitatory synaptogenesis are regulated by inflammatory cytokines and correlate with paralysis severity during experimental autoimmune encephalomyelitis.
Baseline magnetic resonance imaging of the optic nerve provides limited predictive information on short-term recovery after acute optic neuritis.
Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity.
[The use of therapeutic apheresis in neurological diseases and comparison between plasma exchange and immunoadsorption].
[Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.
High prevalence of vitamin D deficiency and cancer in Saudi Arabian populations: Can we hypothesize a link?
Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination.
Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome.
Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis.
Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection.
[Contribution of cerebral magnetic resonance imaging to etiological investigation of uveitis.]
Pages
« first
‹ previous
…
624
625
626
627
628
629
630
631
632
…
next ›
last »